



**The Third Regional Education Meeting on Supportive Care in Cancer Patients
for Eastern Europe and Balkan Region
November 29-30, 2019 Belgrade, Serbia
In collaboration with MASCC, ESO, ESGO, IPOS and International Centre for
Genetic Engineering and Biotechnology (ICGEB)**

Day 1, Nov 29 2019, Friday

08:00-09:00 **REGISTRATION**

09:00-09:15 **OPENING CEREMONY**

09:15-09:35 **PLENARY LECTURE**

Supportive Care Makes Excellent Cancer Care Possible, *J.Herrstedt, Denmark*

OPENING LECTURES

09:35-09:50 **Integrated model of supportive care service: an example from France, *F. Scotte, France***

09:50-10:05 **Integrated model of supportive care service, the role of PROs: *R. Popescu, Switzerland***

SYMPTOMS AND TOXICITIES (20 min lectures + 10 min discussion)

10:05-10:35 **History of CINV prevention: from the dark ages to the present, *F. Roila, Italy***

ESMO 2018 CANCER PAIN GUIDELINES

10:35 - 11:05 **General principles of pain management: the focus on opioids, *S. Ahmedzai, UK***

11:05 -11:35 **Bone / Neuropathic Pain, *J. Dimitrijević, Serbia***

11:35-12:00 **COFFEE BREAK (I)**

12:00-12:20 **The role of radiotherapy in the treatment of bone pain, *T. Arsenijević, Serbia***

12:20-12:40 **Interventional approaches for cancer pain management, *A. Vadalouca, Greece***

12:40-13:00 **Oncology and philosophy, *I. Boukovinas, Greece***

13:00-14:00 **LUNCH**

14:00-14:45 **MEET THE EXPERT : PAIN**

Moderator: D. Jovanović, Serbia

- *Case presentation (10 min): M.Ristić, Serbia*
- *Expert Discussion (15 min):S. Ahmedzai, UK*
- *Q&A from the audience (15 min)*
- *Take home messages: moderator (5 min)*

14:45-15:15 **Psychooncology:** *Csaba Dégi, Romania*

15:15 - 15:45 COFFEE BREAK (II)

15:45 - 16:45 **MEET THE EXPERT : PSYCHOONCOLOGY**

Moderator: *Vesna Kesić, Serbia*

- *Case presentation: Snežana Mijalković (10 min)*
- *Expert discussion: Csaba Degi & Vesna Kesić (10 minutes)*
- *Q&A from the audience: 10 minutes*
- *Case presentation: Marija Andrijić (10 min)*
- *Expert discussion: Csaba Degi & Vesna Kesić (10 minutes)*
- *Q&A from the audience: 10 minutes*

16:45-17:15 **Cachexia,** *J Arends; Germany*

17:15-17:45 **How can medical ethics lead to provide better treatment,** *E. Angellier, France*

Day 2, Nov 30, 2019 Saturday

SYMPTOMS AND TOXICITIES (20 min lectures + 10 min discussion)

In collaboration with International Centre for Genetic Engineering and Biotechnology, Trieste, Italy

09:00-09:30 **Guidelines for the management of immune-related adverse effects,** *M. Aapro, Switzerland*

09:30-10:00 **Mucositis: ESMO / MASCC guidelines,** *D. Keefe, Australia*

10:00-10:30 **Oral mucositis associated with targeted therapies,** *NS. Treister, USA*

10:30-11:00 **Laser treatment of mucositis and dermatitis induced by anticancer treatment:** *G. Ottaviani, Italy*

11:00-11:30 COFFEE BREAK

11:30-12:15 **MEET THE EXPERT: Mucositis in H/N cancer patients**

Moderator: *NS. Treister, USA*

- *Case presentation (10 min) –N. Jovanović , Serbia*
- *Expert Discussion(15 min) – D. Keefe*
- *Q&A from the audience (15 min)*
- *Take home messages: moderator (5 min)*

12:15-12:45 **Diarrhea, ESMO guidelines:** *J. Andreyev, UK*

12:45-13:30 **MEET THE EXPERT: Mucositis, bone marrow transplantation**

Moderator: *G.Ottaviani, Italy*

- *Case presentation (10 min) – A. Vidović*
- *Expert Discussion (15 min) – NS. Treister , USA*
- *Q&A from an audience (15 min)*
- *Take home message: moderator (5 min)*

13:30- 14:00 Constipation, ESMO 2018 guidelines *F. Scotte , France*

14:00- 15:00 LUNCH

15:00- 16:30 WORKSHOP: The integration of supportive care into oncology: mucositis, diarrhea, laser treatment of mucositis / dermatitis

LAMPO study: laser therapy of oral mucositis in pediatric patients,

- *F. Verzegnassi, Italy (15 min)*
 - *Case report: Skin toxicity of vemurafenib in patient with melanoma (10 min) - A.Zilić*
 - *Panel Discussion (15 min)*
 - *Case report: Managing life-threatening diarrhea induced by afatinib in patient with metastatic NSCLC (10 min) - F.Djordjević*
 - *Panel Discussion (15 min)*
 - *Case report: A fatal cardiac toxicity of pembrolizumab (10min) – J.Spasić*
 - *Panel Discussion (15 min)*

